- Home
- RVNC vs ALMS Comparison
RVNC vs ALMS Comparison
Compare RVNC & ALMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVNC
- ALMS
- Stock Information
- Founded
- RVNC 1999
- ALMS 2021
- Country
- RVNC United States
- ALMS United States
- Employees
- RVNC N/A
- ALMS N/A
- Industry
- RVNC Biotechnology: Pharmaceutical Preparations
- ALMS
- Sector
- RVNC Health Care
- ALMS
- Exchange
- RVNC Nasdaq
- ALMS NYSE
- Market Cap
- RVNC 599.6M
- ALMS 652.3M
- IPO Year
- RVNC 2014
- ALMS 2024
- Fundamental
- Price
- RVNC $5.78
- ALMS $11.91
- Analyst Decision
- RVNC Buy
- ALMS Strong Buy
- Analyst Count
- RVNC 10
- ALMS 6
- Target Price
- RVNC $10.86
- ALMS $30.40
- AVG Volume (30 Days)
- RVNC 1.6M
- ALMS 68.3K
- Earning Date
- RVNC 11-19-2024
- ALMS 11-19-2024
- Dividend Yield
- RVNC N/A
- ALMS N/A
- EPS Growth
- RVNC N/A
- ALMS N/A
- EPS
- RVNC N/A
- ALMS N/A
- Revenue
- RVNC $251,178,000.00
- ALMS N/A
- Revenue This Year
- RVNC $20.36
- ALMS N/A
- Revenue Next Year
- RVNC $31.66
- ALMS N/A
- P/E Ratio
- RVNC N/A
- ALMS N/A
- Revenue Growth
- RVNC 40.23
- ALMS N/A
- 52 Week Low
- RVNC $2.30
- ALMS $9.54
- 52 Week High
- RVNC $9.75
- ALMS $13.53
- Technical
- Relative Strength Index (RSI)
- RVNC 56.47
- ALMS N/A
- Support Level
- RVNC $5.67
- ALMS N/A
- Resistance Level
- RVNC $5.97
- ALMS N/A
- Average True Range (ATR)
- RVNC 0.19
- ALMS 0.00
- MACD
- RVNC 0.06
- ALMS 0.00
- Stochastic Oscillator
- RVNC 78.01
- ALMS 0.00
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.
About ALMS ALUMIS INC
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies.